• Celerion Newsletter
Belfast - Center of Excellence for Respiratory

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • AAHRPP Accreditation
      • Phase I and lla Studies
      • In-hospital Beds
      • Study Experience
      • Belfast – Center of Excellence for Respiratory
      • Early Cardiac Services
      • Hybrid Phase I/ECG Core Lab
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • Recruitment
    • Clinical Pharmacology Sciences
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Data Programming
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process
    • Global Bioanalytical Services
      • Small Molecule
      • Large Molecule
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program and Project Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Clinical Pharmacology Sciences
    • Global Bioanalytical Services
    • Management Team
  • The Biosimilars Alliance
    • The Biosimilars Alliance – Overview
    • The Biosimilars Alliance – Benefits
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Trials
    • Clinical Pharmacology Sciences
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • News & Events
    • Press Room
    • Conferences
    • Symposia
    • Webinars
  • Participate in a Study
  • Careers
    • Message from the CEO
    • Culture
  • Spring 2013 Newsletter
  • Fall 2012 Newsletter
  • Spring 2012 Newsletter

Celerion Europe

Global Bioanalytical Services

Celerion has the experience and capacity to exceed your bioanalytical expectations from method development and validation through rapid sample analysis supporting discovery through late stage clinical trials.

Celerion’s facility in Zürich, Switzerland, is one of the most established laboratories in the industry, with over 25 years of bioanalytical operations experience. The team has the scientific expertise to analyze small and large molecules using the latest technologies and to ensure delivery of quality results on time.

The Celerion team has a strong background in both small and large molecule analysis, thereby offering the flexibility to fulfill client needs. This cross-functional experience translates to faster turnaround times and allows us to develop and validate the right assay to meet clinical and regulatory requirements.

Celerion provides full GLP-certified services in method validation and sample analysis using LC-MS/MS, ELISA, ECL, Western blot, RIA and other technologies.

With one of the largest ligand binding laboratories in Europe, and having more than 25 years experience in immunogenicity testing, the Zürich laboratory is renowned for experience with a wide variety of products, including therapeutic proteins (pegylated or non-pegylated), peptides and antibodies.

Excellent technical expertise, coupled with extensive experience in small and large molecules as well as biomarkers, ensures the delivery of high quality data in a timely manner.

Global SOPs and a harmonized electronic laboratory notebook system enable easy assay transfer between the Celerion bioanalytical laboratories in Europe and North America and ensure compliance with internal and regulated quality standards.

Celerion’s Zürich laboratory is Swissmedic GLP-certified for preclinical and clinical sample analysis. This certification is accepted by other regulatory bodies throughout the OECD, as well as the FDA and Japan’s MHLW.

See also…

Validated Assay List: May Assay List

Article: Case studies from the use of commercial biomarker-protein test kits

Case Study: Bioanalytical Support of Oncology Studies

Case Study: Optimized LC-MS/MS Method for New Observed Metabolite

For more information contact us

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2013 Celerion